首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1774717

全球臨床腫瘤學下一代定序市場

Clinical Oncology Next Generation Sequencing

出版日期: 2025年07月23日 | 出版商:

Global Industry Analysts, Inc. | 英文 462 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球臨床腫瘤學下一代定序市場規模將達到 12 億美元

全球臨床腫瘤學新一代定序市場規模預計在2024年為4.899億美元，預計到2030年將達到12億美元，2024年至2030年的複合年成長率為15.8%。全基因組定序是本報告分析的細分市場之一，預計其複合年成長率為17.7%，到分析期結束時達到7.332億美元。全EXOME定序細分市場在分析期間的複合年成長率估計為14.2%。

美國市場規模估計為 1.335 億美元，中國市場預計複合年成長率為 21.3%

美國臨床腫瘤學新一代定序市場規模預計在2024年達到1.335億美元。作為世界第二大經濟體，中國預計在2030年市場規模將達到2.62億美元，在2024-2030年的分析期間內，複合年成長率為21.3%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為11.5%和14.3%。在歐洲，預計德國市場的複合年成長率約為12.6%。

全球臨床腫瘤學下一代定序市場—主要趨勢與促進因素摘要

為什麼次世代定序儀將改變臨床腫瘤學的模式？

次世代定序(NGS) 技術透過在分子層面上對癌症進行更深入、更精準的理解，徹底改變了臨床腫瘤學。與傳統診斷方法不同，NGS 能夠全面分析癌症基因組，識別基因突變、拷貝數變異、基因融合以及其他對腫瘤表徵至關重要的生物標記。隨著癌症治療日益轉向精準醫療，NGS 在指導個人化治療、預測治療反應以及監測疾病進展和復發方面發揮核心作用。 NGS 能夠快速且經濟高效地處理大量基因組數據，這顯著加速了其在臨床腫瘤學實踐中的應用。腫瘤學家目前正在使用基於 NGS 的檢測方案進行伴隨診斷、標靶治療選擇、免疫治療合格，甚至篩檢遺傳性癌症。這些分子層面的洞察正在改變癌症的診斷、分類和治療方式，從而改善患者的預後並更有效地利用醫療資源。隨著全球癌症發生率持續上升，NGS 正成為現代腫瘤學工作流程中的重要工具，在治療的每個階段都能實現精準決策。

技術進步和平台創新如何推動市場成長？

臨床腫瘤NGS市場由快速的技術進步和定序平台、工作流程和數據解讀工具的持續創新所驅動。從全基因組和全EXOME定序到標靶基因組合，高通量定序技術的不斷發展，為多樣化的臨床需求提供了靈活且可擴展的解決方案。定序速度、準確性和價格的提升，使得NGS在從學術中心到社區腫瘤診所等醫療機構中更加普及。先進的生物資訊學平台現已整合到臨床流程中，能夠根據AMP、ASCO和CAP等國際指南實現自動化變異調用、解讀和報告。此外，基於液態切片的循環腫瘤DNA (ctDNA) NGS檢測作為一種非侵入性、即時的癌症檢測和監測工具，其發展勢頭強勁。小型化測序平台和雲端基礎的資料儲存解決方案進一步簡化了臨床實施。這些技術進步不僅縮短了周轉時間和成本，還將NGS的臨床效用從晚期癌症擴展到早期檢測、篩檢和縱向監測。

臨床實踐趨勢、法規結構和區域動態將在市場擴張中發揮什麼作用？

NGS 在臨床腫瘤學中的應用受到臨床實踐趨勢、監管指南和區域特定醫療保健動態融合的影響。臨床醫生對基因突變對預後和治療影響的認知不斷提高，這推動了標準化基因組檢測作為常規癌症診斷一部分的轉變。 FDA、EMA 和 PMDA 等監管機構正在加快基於 NGS 的伴隨診斷的核准，以促進其融入臨床實踐。同時，支付方對基因組檢測的接受度以及不斷演變的報銷政策，正在推動主要市場的可負擔性和採用率。在北美和西歐等已開發地區，先進的數位基礎設施和先進的醫療保健生態系統正在支援臨床 NGS 的廣泛應用。同時，在亞太地區和拉丁美洲，政府主導的基因組學舉措、不斷擴展的腫瘤治療基礎設施以及私人醫療保健機構不斷增加的投資正在推動市場發展。診斷公司、製藥公司和學術研究機構之間的合作也在推動創新和市場滲透。儘管存在數據解釋複雜和技術純熟勞工短缺等挑戰，但全球向循證癌症醫學的轉變已使 NGS 牢牢佔據了臨床支柱的地位。

影響臨床腫瘤學 NGS 市場的核心成長動力是什麼？

臨床腫瘤學下一代定序市場的成長受到多種因素的驅動，這些因素源自於技術進步、不斷發展的臨床需求和不斷變化的醫療保健服務模式。全球癌症發生率的上升和向精準腫瘤學的轉變極大地推動了對全面分子分析解決方案的需求。定序化學、連接複用和自動化方面的技術突破使 NGS 更快、更可靠、更具成本效益。液態切片和單細胞測序等新型測試形式的出現，正在將 NGS 的應用領域從診斷擴展到即時監控和微小殘留疾病檢測。 NGS 在治療指導中的應用日益增多，尤其是在免疫腫瘤學和標靶治療中，這增強了其臨床相關性。伴隨診斷的日益普及和腫瘤特異性NGS 面板的監管核准，正在加速其在治療中心的應用。 NGS 擴大融入電子健康記錄和數位病理工作流程，正在增強臨床決策支援。此外，公共和私人基因組資料庫的廣泛普及，以及合作研究生態系統的完善，正在豐富NGS資料的解讀。患者認知的提升、個人化醫療的需求以及醫療機構對分子診斷領域投資的不斷增加，進一步推動了全球臨床腫瘤NGS市場的擴張。

部分

技術類型（全基因組定序、全EXOME定序、標靶定序、重定序）、工作流程（NGS 前定序、NGS 定序、NGS 資料分析）、應用（篩檢應用、伴隨診斷應用、其他診斷應用）、最終用途（醫院最終用途、診所最終用途、實驗室最終用途）

受訪公司範例

Agilent Technologies, Inc.
Becton, Dickinson and Company（BD）
Beijing Genomics Institute（BGI）
bioMerieux SA
Bio-Rad Laboratories, Inc.
Caris Life Sciences
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd.
Foundation Medicine, Inc.
Guardant Health, Inc.
Illumina, Inc.
Myriad Genetics, Inc.
Oxford Nanopore Technologies Ltd.
Pacific Biosciences of California, Inc.
Partek Incorporated
PerkinElmer, Inc.
Qiagen NV
Takara Bio Inc.
Thermo Fisher Scientific Inc.
Zymo Research Corporation

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 並未遵循典型的 LLM 或特定產業的 SLM查詢，而是建立了一個從全球專家收集的內容庫，其中包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

The global market for Clinical Oncology Next Generation Sequencing estimated at US$489.9 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 15.8% over the analysis period 2024-2030. Whole Genome Sequencing, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$733.2 Million by the end of the analysis period. Growth in the Whole Exome Sequencing segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$133.5 Million While China is Forecast to Grow at 21.3% CAGR

The Clinical Oncology Next Generation Sequencing market in the U.S. is estimated at US$133.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$262.0 Million by the year 2030 trailing a CAGR of 21.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Clinical Oncology Next Generation Sequencing Market - Key Trends & Drivers Summarized

Why Is Next Generation Sequencing Transforming the Clinical Oncology Landscape?

Next Generation Sequencing (NGS) has revolutionized clinical oncology by enabling a deeper, more precise understanding of cancer at the molecular level. Unlike traditional diagnostic methods, NGS allows for the comprehensive profiling of cancer genomes, identifying genetic mutations, copy number variations, gene fusions, and other biomarkers critical to tumor characterization. As cancer treatment increasingly shifts toward precision medicine, NGS plays a central role in guiding personalized therapies, predicting treatment response, and monitoring disease progression or recurrence. The ability of NGS to process large volumes of genomic data rapidly and cost-effectively has significantly accelerated its adoption in clinical oncology practices. Oncologists are now using NGS-based panels for companion diagnostics, targeted therapy selection, immunotherapy eligibility, and even hereditary cancer screening. This molecular insight is transforming how cancers are diagnosed, classified, and treated, leading to better patient outcomes and more efficient use of healthcare resources. As cancer incidence continues to rise globally, NGS is becoming an indispensable tool in modern oncology workflows, enabling precision-driven decision-making at every stage of care.

How Are Technological Advancements and Platform Innovations Fueling Market Growth?

The clinical oncology NGS market is being propelled by rapid technological advancements and continuous innovation in sequencing platforms, workflows, and data interpretation tools. The evolution of high-throughput sequencing technologies-ranging from whole-genome and whole-exome sequencing to targeted gene panels-is offering flexible and scalable solutions tailored to diverse clinical needs. Improvements in sequencing speed, accuracy, and affordability are making NGS more accessible across healthcare settings, from academic centers to community oncology clinics. Advanced bioinformatics platforms are now integrated into clinical pipelines, enabling automated variant calling, interpretation, and reporting in compliance with international guidelines such as those by the AMP, ASCO, and CAP. Moreover, the development of liquid biopsy-based NGS tests-using circulating tumor DNA (ctDNA)-is gaining momentum as a non-invasive, real-time tool for cancer detection and monitoring. Miniaturized sequencing platforms and cloud-based data storage solutions are further simplifying clinical implementation. These technological strides are not only reducing turnaround times and lowering costs but also expanding the clinical utility of NGS beyond advanced-stage cancers into early detection, screening, and longitudinal monitoring.

What Role Do Clinical Practice Trends, Regulatory Frameworks, and Regional Dynamics Play in Market Expansion?

The adoption of NGS in clinical oncology is shaped by a convergence of clinical practice trends, regulatory guidelines, and region-specific healthcare dynamics. There is a growing shift toward standardized genomic testing as part of routine oncology diagnostics, driven by increasing awareness among clinicians about the prognostic and therapeutic implications of genetic mutations. Regulatory authorities such as the FDA, EMA, and PMDA are accelerating approvals for NGS-based companion diagnostics, facilitating integration into clinical practice. Simultaneously, payer acceptance and evolving reimbursement policies for genomic tests are enhancing affordability and adoption across key markets. In developed regions like North America and Western Europe, high digital infrastructure and advanced healthcare ecosystems support widespread use of clinical NGS, while in Asia-Pacific and Latin America, market growth is being fueled by government-led genomics initiatives, expanding oncology care infrastructure, and increasing investments by private healthcare providers. Collaborations between diagnostics companies, pharmaceutical firms, and academic research institutions are also driving innovation and market penetration. Despite challenges such as data interpretation complexity and skilled workforce shortages, the global shift toward evidence-based oncology care is firmly positioning NGS as a clinical mainstay.

What Are the Core Growth Drivers Shaping the Clinical Oncology NGS Market?

The growth in the clinical oncology next generation sequencing market is driven by several factors rooted in technological advancement, evolving clinical needs, and changing healthcare delivery models. The rising global cancer burden and the shift toward precision oncology are significantly increasing the demand for comprehensive molecular profiling solutions. Technological breakthroughs in sequencing chemistry, multiplexing, and automation are making NGS faster, more reliable, and increasingly cost-effective. The emergence of novel testing formats-such as liquid biopsies and single-cell sequencing-is expanding NGS application areas beyond diagnostics into real-time monitoring and minimal residual disease detection. Expanding use of NGS for therapy guidance, particularly in immuno-oncology and targeted treatments, is boosting its clinical relevance. Growing availability of companion diagnostics and regulatory approvals for tumor-specific NGS panels are accelerating adoption across treatment centers. The increasing integration of NGS into electronic medical records and digital pathology workflows is enhancing clinical decision support. Moreover, the proliferation of public and private genomic databases, along with collaborative research ecosystems, is enriching the interpretation of NGS data. Patient awareness, demand for personalized care, and growing healthcare investments in molecular diagnostics are further propelling the global expansion of the clinical oncology NGS market.

SCOPE OF STUDY:

The report analyzes the Clinical Oncology Next Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing); Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis); Application (Screening Application, Companion Diagnostics Application, Other Diagnostics Application); End-Use (Hospitals End-Use, Clinics End-Use, Laboratories End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

Agilent Technologies, Inc.
Becton, Dickinson and Company (BD)
Beijing Genomics Institute (BGI)
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
Caris Life Sciences
Eurofins Scientific S.E.
F. Hoffmann-La Roche Ltd.
Foundation Medicine, Inc.
Guardant Health, Inc.
Illumina, Inc.
Myriad Genetics, Inc.
Oxford Nanopore Technologies Ltd.
Pacific Biosciences of California, Inc.
Partek Incorporated
PerkinElmer, Inc.
Qiagen N.V.
Takara Bio Inc.
Thermo Fisher Scientific Inc.
Zymo Research Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Clinical Oncology Next Generation Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Cancer Incidence Worldwide Throws the Spotlight on Next Generation Sequencing as a Cornerstone in Precision Oncology
- Shift Toward Personalized Cancer Therapy Spurs Demand for Comprehensive Genomic Profiling Using NGS Platforms
- Expansion of Companion Diagnostics and Targeted Therapy Approaches Strengthens Business Case for Oncology-Focused NGS Testing
- Rapid Technological Advancements in Sequencing Speed and Cost Efficiency Drive Widespread Clinical Adoption of NGS
- Growing Use of Tumor Mutation Burden and Biomarker Discovery Expands Addressable Market Opportunity for Clinical NGS
- Integration of NGS in Oncology Care Pathways Enhances Treatment Stratification and Prognostic Decision-Making
- Regulatory Approvals and Reimbursement Policies Accelerate Market Penetration of NGS-Based Oncology Panels
- Increasing Adoption of Liquid Biopsy-Based NGS Tests Throws the Spotlight on Non-Invasive Cancer Detection Solutions
- Emerging Role of NGS in Minimal Residual Disease Monitoring and Recurrence Prediction Fuels Demand for High-Sensitivity Panels
- Clinical Trials and Pharma Partnerships for Oncology Drug Development Propel Use of NGS in Biomarker-Driven Research
- Rising Use of Comprehensive Genomic Panels Over Single-Gene Tests Drives Demand for Scalable and Modular NGS Platforms
- Growth in Cancer Molecular Tumor Boards and Genomics-Guided Decision Support Systems Enhances Clinical Utility of NGS Data
- OEM Focus on Turnkey NGS Workflows and Automated Bioinformatics Pipelines Boosts Adoption in Clinical Oncology Labs
- Global Expansion of Cancer Genomics Programs and National Precision Medicine Initiatives Strengthens Market Growth Outlook
- Long-Term Shift Toward Data-Driven Oncology and Personalized Medicine Sustains Demand for Advanced Clinical NGS Solutions
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Clinical Oncology Next Generation Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Whole Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Whole Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Whole Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Whole Exome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Whole Exome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Whole Exome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Targeted Sequencing & Resequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Targeted Sequencing & Resequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Targeted Sequencing & Resequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for NGS Pre-Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for NGS Pre-Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for NGS Pre-Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for NGS Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for NGS Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for NGS Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for NGS Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for NGS Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for NGS Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Companion Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Companion Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Companion Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 38: World Recent Past, Current & Future Analysis for Other Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 39: World Historic Review for Other Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 40: World 15-Year Perspective for Other Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 41: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 44: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 49: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 50: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: USA Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 52: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
CANADA
- TABLE 53: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 59: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: Canada Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 61: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 62: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Canada Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 64: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
JAPAN
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 65: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 68: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Japan Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 70: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 71: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: Japan Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 73: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 74: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 75: Japan Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 76: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
CHINA
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 77: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: China Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 79: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 80: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: China Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 82: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 83: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: China Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 85: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 86: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: China Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 88: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
EUROPE
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 89: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 90: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 91: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 92: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 93: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 94: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 95: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 96: Europe Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 97: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 98: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 99: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 100: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 101: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 102: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 103: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
FRANCE
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 104: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 105: France Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 106: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 107: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 108: France Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 109: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 110: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 111: France Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 112: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 113: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 114: France Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 115: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
GERMANY
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 116: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 117: Germany Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 118: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 119: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 120: Germany Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 121: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 122: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 123: Germany Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 124: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 125: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 126: Germany Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 127: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
ITALY
- TABLE 128: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 129: Italy Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 130: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 131: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 132: Italy Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 133: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 134: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 135: Italy Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 136: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 137: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 138: Italy Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 139: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 140: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 141: UK Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 142: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 143: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 144: UK Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 145: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 146: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 147: UK Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 148: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 149: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 150: UK Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 151: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
SPAIN
- TABLE 152: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 153: Spain Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 154: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 155: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 156: Spain Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 157: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 158: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 159: Spain Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 160: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 161: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 162: Spain Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 163: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 164: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 165: Russia Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 166: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 167: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 168: Russia Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 169: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 170: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 171: Russia Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 172: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 173: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 174: Russia Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 175: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 177: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 178: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 180: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 181: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 183: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 184: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 186: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 187: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 189: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 190: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 192: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 193: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 195: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 196: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 198: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 199: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 201: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 202: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
AUSTRALIA
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 203: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 204: Australia Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 205: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 206: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 207: Australia Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 208: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 209: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 210: Australia Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 211: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 212: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 213: Australia Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 214: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
INDIA
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 215: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 216: India Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 217: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 218: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 219: India Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 220: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 221: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 222: India Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 223: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 224: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 225: India Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 226: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 227: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 228: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 229: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 230: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 231: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 232: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 233: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 234: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 235: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 236: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 237: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 238: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 240: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 246: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 249: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
LATIN AMERICA
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 251: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 252: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 253: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 254: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 255: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 256: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 257: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 258: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 259: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 260: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 261: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 262: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 263: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 264: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 265: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 266: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 267: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 268: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 269: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 270: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 271: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 272: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 273: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 274: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 275: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 276: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 277: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 278: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 279: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 280: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 281: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 282: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 283: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 284: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 285: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 286: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 287: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 288: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 289: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
MEXICO
- TABLE 290: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 291: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 292: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 293: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 294: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 295: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 296: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 297: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 298: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 299: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 300: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 301: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 306: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 307: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 309: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 310: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 312: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 313: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
MIDDLE EAST
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 314: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 315: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 316: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 317: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 318: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 319: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 320: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 321: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 322: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 323: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 324: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 325: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 326: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 327: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 328: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
IRAN
- TABLE 329: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 330: Iran Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 331: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 332: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 333: Iran Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 334: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 335: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 336: Iran Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 337: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 338: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 339: Iran Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 340: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 341: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 342: Israel Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 343: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 344: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 345: Israel Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 346: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 347: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 348: Israel Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 349: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 350: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 351: Israel Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 352: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 354: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 355: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 357: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 358: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 360: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 361: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 363: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 364: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 365: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 366: UAE Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 367: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 368: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 369: UAE Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 370: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 371: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 372: UAE Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 373: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 374: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 375: UAE Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 376: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 378: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 379: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 381: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 382: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 384: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 385: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 387: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 388: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
AFRICA
- Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 389: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 390: Africa Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 391: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
- TABLE 392: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 393: Africa Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 394: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
- TABLE 395: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 396: Africa Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 397: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
- TABLE 398: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 399: Africa Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 400: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030